Cost-Effectiveness Analysis of Lebrikizumab versus Dupilumab for Patients with Severe Atopic Dermatitis in Austria.
文献摘要
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant economic burden. This study evaluated the cost-effectiveness of lebrikizumab compared to dupilumab for adults and adolescents with severe AD from an Austrian healthcare payer's perspective. Methods A cost-effectiveness analysis, based on the NICE assessment's TA986 model, was conducted, comprising a decision tree for the first year and a Markov model for long-term outcomes. The analysis adopted a healthcare system perspective, discount rate (3%) and applied Austrian-specific data, costs and quality of life measures. Two scenarios assessed the robustness of the base case analysis. Results The base case analysis showed lebrikizumab was associated with lower total costs (€128,961 vs €133,870) and slightly lower QALYs (16.53 vs 16.56) compared to dupilumab over a lifetime horizon. The primary driver of cost savings was lower drug acquisition costs for lebrikizumab (-€5,349). Scenario analyses with different economic and clinical data demonstrated cost-effectiveness for lebrikizumab. Discussion This economic evaluation suggests lebrikizumab is a potential cost-saving alternative to dupilumab based on the base case analysis of this health economic model for severe AD treatment in Austria, with comparable clinical efficacy. Consequently, lebrikizumab has been reimbursed in Austria since January 2025 as the second biological therapeutic option alongside dupilumab, following national pricing and reimbursement rules.